Publications by authors named "Samuel Agus"

Claim this Profile
B
BIO101 in Sarcopenic Seniors at Risk of Mobility Disability: Results of a Double-Blind Randomised Interventional Phase 2b Trial.
Roger A Fielding, Michael M Dao, Kevin Cannon, Moise Desvarieux, Sam S Miller, Samuel Agus

J Cachexia Sarcopenia Muscle· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A constrained disorder principle-based second-generation artificial intelligence digital medical cannabis system: A real-world data analysis.
Noa Hurvitz, Hillel Lehman, Yoav Hershkovitz, Yotam Kolben, Khurram Jamil, Samuel Agus

J Public Health Res· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Improving the response to lenvatinib in partial responders using a Constrained-Disorder-Principle-based second-generation artificial intelligence-therapeutic regimen: a proof-of-concept open-labeled clinical trial.
Tal Sigawi, Ram Gelman, Ofra Maimon, Amal Yossef, Nila Hemed, Samuel Agus

Front Oncol· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Feasibility Open-Labeled Clinical Trial Using a Second-Generation Artificial-Intelligence-Based Therapeutic Regimen in Patients with Gaucher Disease Treated with Enzyme Replacement Therapy.
Noa Hurvitz, Tama Dinur, Shoshana Revel-Vilk, Samuel Agus, Marc Berg

J Clin Med· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of oral 20-hydroxyecdysone (BIO101), a MAS receptor activator, in adults with severe COVID-19 (COVA): a randomized, placebo-controlled, phase 2/3 trial.
Suzana Margareth Lobo, Gaétan Plantefève, Girish Nair, Adilson Joaquim Cavalcante, Nara Franzin de Moraes, Samuel Agus

EClinicalMedicine· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A second-generation artificial intelligence-based therapeutic regimen improves diuretic resistance in heart failure: Results of a feasibility open-labeled clinical trial.
Ram Gelman, Noa Hurvitz, Rima Nesserat, Yotam Kolben, Dean Nachman, Samuel Agus

Biomed Pharmacother· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A digital health platform for assisting the diagnosis and monitoring of COVID-19 progression: An adjuvant approach for augmenting the antiviral response and mitigating the immune-mediated target organ damage.
Yuval Ishay, Assaf Potruch, Asaf Schwartz, Marc Berg, Khurram Jamil, Samuel Agus

Biomed Pharmacother· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The patient experience with DSM-5-defined binge eating disorder: characteristics, barriers to treatment, and implications for primary care physicians.
Barry K Herman, Shima Safikhani, David Hengerer, Norman Atkins, Andy Kim, Samuel Agus

Postgrad Med· September 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Low-dose aspirin prophylaxis and risk of intracranial hemorrhage in patients older than 60 years of age with mild or moderate head injury: a prospective study.
Sergey Spektor, Samuel Agus, Vladimir Merkin, Shlomo Constantini

J Neurosurg· October 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis